Brief: Atara Biotherapeutics Submits Tabelecleucel (Tab-Cel®) Biologics License Application
20/05/2024 14:30
May 20 (Reuters) - Atara Biotherapeutics Inc ATRA.O :
* ATARA BIOTHERAPEUTICS SUBMITS TABELECLEUCEL (TAB-CEL®)
BIOLOGICS
LICENSE APPLICATION FOR TREATMENT OF EPSTEIN-BARR VIRUS POSITIVE
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE WITH U.S. FDA
* ATARA BIOTHERAPEUTICS INC - ACCEPTANCE OF BLA WILL TRIGGER
$20
MILLION MILESTONE PAYMENT FROM PIERRE FABRE LABORATORIES
* ATARA ELIGIBLE FOR ADDITIONAL $60M UPON FDA APPROVAL
Source text for Eikon: ID:nBw7n40HMa
Further company coverage: ATRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atara Biotherapeutics
See all newsAtara Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atara Biotherapeutics Q2 revenue falls on deferred revenue recognition
Brief: Atara Biotherapeutics Q2 EPS USD -0.32
Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a share - Earnings Preview
Brief: Atara Biotherapeutics - May Offer Up To $79.27 Million In Common Stock As Of May 12, 2026 - SEC Filing